Caladrius Biosciences, Inc. (NASDAQ:CLBS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Wednesday. The brokerage presently has a $3.25 target price on the biotechnology company’s stock. Zacks Investment Research‘s price target suggests a potential upside of 8.70% from the company’s previous close.

According to Zacks, “Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York. “

CLBS has been the subject of several other research reports. ValuEngine upgraded shares of Caladrius Biosciences from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Caladrius Biosciences in a research note on Friday, July 21st.

Caladrius Biosciences (NASDAQ CLBS) traded down $0.06 during trading on Wednesday, hitting $2.99. 57,400 shares of the stock traded hands, compared to its average volume of 58,844. Caladrius Biosciences has a 12-month low of $2.63 and a 12-month high of $7.79.

Caladrius Biosciences (NASDAQ:CLBS) last released its earnings results on Thursday, November 9th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.79) by $0.41. Caladrius Biosciences had a negative net margin of 84.10% and a negative return on equity of 96.80%. research analysts expect that Caladrius Biosciences will post -2.73 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Caladrius Biosciences, Inc. (CLBS) Raised to Buy at Zacks Investment Research” was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at

A number of hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in Caladrius Biosciences by 2.8% in the 2nd quarter. Vanguard Group Inc. now owns 155,380 shares of the biotechnology company’s stock worth $723,000 after buying an additional 4,163 shares during the period. KCG Holdings Inc. increased its stake in Caladrius Biosciences by 74.6% in the 1st quarter. KCG Holdings Inc. now owns 36,291 shares of the biotechnology company’s stock worth $183,000 after buying an additional 15,501 shares during the period. Finally, Renaissance Technologies LLC increased its stake in Caladrius Biosciences by 34.3% in the 1st quarter. Renaissance Technologies LLC now owns 97,552 shares of the biotechnology company’s stock worth $491,000 after buying an additional 24,900 shares during the period. 6.36% of the stock is currently owned by institutional investors.

Caladrius Biosciences Company Profile

Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.

Receive News & Ratings for Caladrius Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.